Board of Directors

Richard A. Parker,

Richard A. Parker serves as Chief Medical Officer for Arcadia Healthcare Solutions. Previously, Dr. Parker was an internist with a 30-year history at Beth Israel Deaconess Medical Center. From 2001 until 2015, Rich served as the Medical Director and Chief Medical Officer for the 2200 doctor Beth Israel Deaconess Care Organization. He oversaw the physician network evolution from a fee for service payment system to a nationally recognized global payment Pioneer Accountable Care Organization. Dr. Parker’s other areas of expertise include end of life care, medical malpractice, care of the mentally ill, electronic medical records and population health management.

Dr. Parker served as Assistant Professor of Medicine at Harvard Medical School.  Dr. Parker graduated from Harvard College in 1978 and the Dartmouth-Brown Program in Medicine in 1985.

Paolo Paoletti,

Paolo Paoletti is currently the CEO at GammaDelta Therapeutics, a biotech company focused on leveraging gamma delta T cells which are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. He was formerly the first appointed president of GSK Oncology, where he was responsible for championing an organization of more than 2,000 professionals around the world dedicated to fighting the causes and impacts of cancer.  During his tenure at GSK, seven new medicines to treat different kinds of cancer were approved globally, generating annual sales of about US$2 billion. In 2014, GSK sold the Oncology business for US$16 billion to Novartis in a complex three-way transaction.

Prior to joining GSK, Dr. Paoletti was Vice President of Oncology Clinical Research at Lilly, where he developed ALIMTA (> US$2 Billion annual sales). Most recently Dr. Paoletti was Chief Executive Officer of Kesios Therapeutics Limited. Dr. Paoletti is currently a non-executive director for Genmab, PsiOxus Therapeutics (Chairman of the Board), FORMA Therapeutics and Nucana Biomed.  Dr. Paoletti has a degree in Medicine from the University of Pisa (Italy) where he was Professor in Pulmonary Diseases.

Thomas L. Patz,

Thomas L. Patz is the Chief Operating Officer of Grid Therapeutics. For over 20 years prior to joining Grid, Mr. Patz served as Executive Vice President, Strategic Initiatives, and General Counsel of MICROS Systems, Inc., a publicly traded software company.  During his tenure at MICROS, Mr. Patz was instrumental in architecting over 30 transactions, including the sale of MICROS to Oracle Corporation in 2014 for $5.3 Billion.

Mr. Patz holds an AB degree from Brown University and a Juris Doctorate from the University of Virginia School of Law.

Edward (Ned) Patz,
Jr., MD

Edward Patz is a co-founder and CEO of Grid Therapeutics. For over 25 years, Dr. Patz has been a clinical radiologist and led a basic science laboratory at Duke University Medical Center focused on lung cancer biology and early cancer detection.

Dr. Patz is a member of the Fleischner Society, the International Association for the Study of Lung Cancer, and the Society of Thoracic Radiology. He holds a BS in physics from Duke University, was a researcher in High Energy Physics at Harvard University and received his MD at the University of Maryland. He is currently the James and Alice Chen Professor of Radiology, Professor in Pharmacology and Cancer Biology, and Professor in Pathology at Duke. Dr. Patz previously served on the faculty at Brigham and Women’s Hospital, Harvard Medical School, and the Dana-Farber Cancer Institute.

Kevin Schulman,

Dr. Schulman is a Professor of Medicine, Associate Chair of Business Development and Strategy in the Department of Medicine, Director of Industry Partnerships and Education for the Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and, by courtesy, Professor of Economics at Stanford’s Graduate School of Business in June, 2018.

Dr. Schulman’s research interests include organizational innovation in health care, health care policy and health economics.  With over 300 original articles and 40 case studies/book chapters, Kevin Schulman has had a broad impact on health policy. He is a member of the editorial/advisory boards of the American Heart Journal, Health Policy, Management and Innovation (www.HMPI.Org), and Senior Associate Editor of Health Services Research.

Prior to coming to Stanford, Dr. Schulman served as a Professor of Medicine at Duke University, directed the Health Sector Management Program at Duke’s Fuqua School of Business for a dozen years, created and directed the Duke University Masters of Management in Clinical Informatics Program, and served as a Visiting Professor and Visiting Scholar at Harvard Business School. He is a co-founder of Bivarus (exit January, 2018), co-founder and Managing Member of Faculty Connection, LLC. He is a graduate of Dartmouth College, the New York University School of Medicine, and The Wharton Health Care Management Program.